top of page

THE COST OF MANIPULATION: THE IRRESPONSIBLE ABUSE OF TECHNOLOGICAL OPACITY IN BIG PHARMA

We are delighted to announce the publication of a new article on our partner platform the Corporate Social Responsibility and Business Ethics Blog authored by Sonia Leann Jackson and entitled "The Cost of Manipulation: The Irresponsible Abuse of Technological Opacity in the Pharmaceutical Industry"

This article, which builds, inter alia, on the research conducted during the NATO-funded project Whistling at the Fake (https://www.corporatecrime.co.uk/whistling-at-the-fake) that was coordinated by Dr. Costantino Grasso, explores the risks associated with the irresponsible use of technology in the pharmaceutical industry, including scientific manipulation in drug trials, scientific misrepresentation through ghost-written publications, and abuse of technology through the misrepresentation of risks.


The article highlights the negative impacts of these practices on patients, healthcare professionals, and society as a whole. It discusses the problems caused by selective reporting and manipulation of data, ghost-writing, and the misrepresentation of risks associated with drugs after they are on the market. The article emphasizes the need for transparency, legislation, and whistleblowers to ensure the integrity of the pharmaceutical industry and protect the public from harm.


Access the article on the Corporate Social Responsibility and Business Ethics Blog here:


Download the article in PDF format:

Sonia Jackson (2023) Big Pharma and Technology - CSR Blog
.pdf
Download PDF • 268KB

Disclaimer


The views, opinions, and positions expressed within all posts are those of the author(s) alone and do not represent those of the Corporate Crime Observatory or its editors. The Corporate Crime Observatory makes no representations as to the accuracy, completeness, and validity of any statements made on this site and will not be liable for any errors, omissions, or representations. The copyright of this content belongs to the author(s) and any liability concerning the infringement of intellectual property rights remains with the author(s).


#CSR #business #corporations #misinformation #disinformation #OxyContin #Purdue #businessethics #pharmaceuticalindustry #healthcare #medications #drugtrials #science #ethics #transparency #patientrights #FDA #ghostwriting #medicaljournals #healthcareprofessionals #publichealth #safety #effectiveness #pricing #competition #innovation #cartels #technology #risks #sideeffects #addiction #patientsafety #research #regulation #PharmaceuticalIndustry #DrugDevelopment #PriceGouging #CorporateCartels #ScientificManipulation #DrugTrials #ScientificMisrepresentation #GhostWrittenPublications #AbuseOfTechnology #NegativeSideEffects #PatientSafety #HealthcareProfessionals #Transparency #ClinicalTrials #FDAOversight #EthicalStandards #HostileInformation #HarmfulConsequences #PatientRights #ConsumerProtection #Healthcare #SocietyImpact #PharmaFraud #PharmaScandal #PharmaEthics #PharmaCorruption #PharmaAccountability #DrugSafety #DrugAddiction #PharmaTransparency #CSRBlog #CCO #corporatecrimeobservatory

Commentaires


bottom of page